-
EP4142702
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4142702
| EP4142702 - E PROTEIN CHANNEL BLOCKERS AND ORF3 INHIBITORS AS ANTI-COVID-19 AGENTS [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 03.02.2023 Database last updated on 24.08.2024 | |
| Former | The international publication has been made Status updated on 05.11.2021 | ||
| Former | unknown Status updated on 22.06.2021 | Most recent event Tooltip | 25.05.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Hi-Tech Park Edmond J. Safra Campus Givat Ram P.O.B 39135 91390 Jerusalem / IL | [2023/10] | Inventor(s) | 01 /
ARKIN, Isaiah 9083600 Har Adar / IL | 02 /
SINGH TOMAR, Prabhat Pratap 9767101 Jerusalem / IL | 03 /
KRUGLIAK, Miriam 9063100 Beit El / IL | [2023/10] | Representative(s) | Boult Wade Tennant LLP Salisbury Square House 8 Salisbury Square London EC4Y 8AP / GB | [2023/10] | Application number, filing date | 21731597.7 | 02.05.2021 | [2023/10] | WO2021IL50501 | Priority number, date | US202063018598P | 01.05.2020 Original published format: US 202063018598 P | US202063117619P | 24.11.2020 Original published format: US 202063117619 P | [2023/10] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021220284 | Date: | 04.11.2021 | Language: | EN | [2021/44] | Type: | A1 Application with search report | No.: | EP4142702 | Date: | 08.03.2023 | Language: | EN | The application published by WIPO in one of the EPO official languages on 04.11.2021 takes the place of the publication of the European patent application. | [2023/10] | Search report(s) | International search report - published on: | EP | 04.11.2021 | Classification | IPC: | A61K31/13, A61K31/155, A61K31/357, A61K31/375, A61K31/40, A61K31/433, A61K31/4427, A61K31/495, A61K31/506, A61K31/517, A61K31/64, A61K31/704, A61K31/7072, A61K31/7076, A61K31/708 | [2023/10] | CPC: |
A61K45/06 (EP,IL);
A61K31/13 (EP,IL);
A61K31/155 (EP,IL);
A61K31/357 (EP,IL);
A61K31/375 (EP,IL);
A61K31/40 (EP,IL);
A61K31/433 (EP,IL);
A61K31/4427 (EP,IL);
A61K31/495 (EP,IL);
A61K31/506 (EP,IL);
A61K31/517 (EP,IL);
A61K31/64 (EP,IL);
A61K31/704 (EP,IL);
A61K31/7072 (EP,IL);
A61K31/7076 (EP,IL);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/10] | Title | German: | E-PROTEIN-KANALBLOCKER UND ORF3-INHIBITOREN ALS ANTI-COVID-19-MITTEL | [2023/10] | English: | E PROTEIN CHANNEL BLOCKERS AND ORF3 INHIBITORS AS ANTI-COVID-19 AGENTS | [2023/10] | French: | INHIBITEURS DE CANAL DE PROTÉINE E ET INHIBITEURS DE L'ORF3 UTILISÉS EN TANT QU'AGENTS ANTI-COVID-19 | [2023/10] | Entry into regional phase | 30.11.2022 | National basic fee paid | 30.11.2022 | Designation fee(s) paid | 30.11.2022 | Examination fee paid | Examination procedure | 30.11.2022 | Examination requested [2023/10] | 30.11.2022 | Date on which the examining division has become responsible | 08.06.2023 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 20.04.2023 | Renewal fee patent year 03 | 24.05.2024 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XP]CN111773282 (GOLDEN HEALTH FOSHAN TECH CO LTD) [XP] 6,13 * claims 2, 9 *; | [XPI] - TOMAR PRABHAT PRATAP SINGH ET AL, "Blockers of the SARS-CoV-2 3a Channel Identified by Targeted Drug Repurposing", VIRUSES, vol. 13, no. 3, doi:10.3390/v13030532, (20210323), page 532, URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8004704/pdf/viruses-13-00532.pdf, XP055822458 [XP] 1-4,8-12,14 * the whole document * [I] 5 DOI: http://dx.doi.org/10.3390/v13030532 | [XP] - Tomar Prabhat Pratap Singh ET AL, "Significance Statement", bioRxiv, doi:10.1101/2021.02.24.432490, (20210224), pages 1 - 6, URL: https://www.biorxiv.org/content/10.1101/2021.02.24.432490v1.full.pdf, (20210805), XP055830277 [XP] 1-4,7,8,10-12,14 * the whole document * DOI: http://dx.doi.org/10.1101/2021.02.24.432490 | [XPI] - SINGH TOMAR PRABHAT PRATAP ET AL, "SARS-CoV-2 E protein is a potential ion channel that can be inhibited by Gliclazide and Memantine", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Amsterdam NL, (20200901), vol. 530, no. 1, doi:10.1016/j.bbrc.2020.05.206, ISSN 0006-291X, pages 10 - 14, XP055797629 [XP] 1-4,7,10-12 * the whole document * [I] 5 DOI: http://dx.doi.org/10.1016/j.bbrc.2020.05.206 | [XPI] - JIMÉNEZ-JIMÉNEZ FÉLIX JAVIER ET AL, "Anti-Inflammatory Effects of Amantadine and Memantine: Possible Therapeutics for the Treatment of Covid-19?", JOURNAL OF PERSONALIZED MEDICINE, (20201209), vol. 10, no. 4, doi:10.3390/jpm10040217, ISSN 2075-4426, page 217, XP055797833 [XP] 1-4,7,10-12 * the whole document * * figure 2 * [I] 5 DOI: http://dx.doi.org/10.3390/jpm10040217 | [XP] - UGUREL OSMAN MUTLUHAN ET AL, "Evaluation of the potency of FDA-approved drugs on wild type and mutant SARS-CoV-2 helicase (Nsp13)", INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, ELSEVIER BV, NL, vol. 163, doi:10.1016/J.IJBIOMAC.2020.09.138, ISSN 0141-8130, (20200924), pages 1687 - 1696, (20200924), XP086300468 [XP] 1-3,8,10,11,14 * abstract * * table 3 * DOI: http://dx.doi.org/10.1016/j.ijbiomac.2020.09.138 | by applicant | US3358001 | US3391142 | US4235871 | US4501728 | US4666828 | US4683202 | US4801531 | US4837028 | US5019369 | US5192659 | US5272057 | US5891885 | US5919826 | US6187338 | WO03055876 | US7332605 | WO2012135405 | WO2014125499 | US9421223 | WO2016181409 | US9878984 | - "GenBank", Database accession no. QIH45055.1 | - CAS, no. 356057-34-6 | - "UniProt", Database accession no. PODTC3 | - ASTRAHAN, P. et al., Acta, (20110000), vol. 1808, pages 394 - 8 | - SANTNER, P. et al., Biochemistry, (20180000), vol. 57, pages 5949 - 5956 | - TAUBE, R.ALHADEFF, R.ASSA, D.KRUGLIAK, M.ARKIN, I. T., PLoS One, (20140000), vol. 9, page e105387 | - FRESHNEY, Culture of Animal Cells - A Manual of Basic Technique, Appleton & Lange, (19940000), vol. I-III | - "Recombinant DNA", WATSON et al., Scientific American Books | - MIESENBOCK, GDE ANGELIS, D AROTHMAN, J E., Nature, (19980000), vol. 394, pages 192 - 5 | - STUMPE, S.BAKKER, E. P., Arch Microbiol, (19970000), vol. 167, pages 126 - 36 | - BERTANI, G, J Bacteriol, (19510000), vol. 62, pages 293 - 300 | - ASTRAHAN, P. et al., Biochim Biophys Acta, (20110000), vol. 1808, pages 394 - 8 | - TOMAR, P. P. S.OREN, R.KRUGLIAK, M.ARKIN, I. T., Viruses, (20190000), vol. 11 | - ASSA, D.ALHADEFF, R.KRUGLIAK, M.ARKIN, I. T., J. Mol Biol, (20160000), vol. 428, pages 4209 - 4217 | - PINTO, L. H.HOLSINGER, L. J.LAMB, R. A., Cell, (19920000), vol. 69, pages 517 - 28 |